Bosutinib – related pleural effusion in patients with chronic myeloid leukemia

References

• Yilmaz U, Eskazan AE. Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years? Expert Rev Hematol. 2020;13(10):1035-1038.
   Google Scholar
• Tiribelli M, Eskazan AE. Tyrosine kinase inhibitor sequencing in patients with chronic myeloid Leukemia. Oncol Ther. 2019;7(2):95–100.
   PubMed Web of Science ®Google Scholar
• Eşkazan AE. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities – which TKI is the safest? Br J Clin Pharmacol. 2019;85(10):2241–2243.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Ozmen D. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events – is better always good? Expert Rev Hematol. 2017;10(7):583–586.
   PubMed Web of Science ®Google Scholar
• Kirkizlar O, Eskazan AE. Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Expert Rev Quality Life in Cancer Care. 2016;1(5):353‐359.
   Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398–1405.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Soysal T, Ongoren S, et al. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica. 2011;96(3):e15–e17.
   PubMed Web of Science ®Google Scholar
• Özgür Yurttaş N, Eşkazan AE. Dasatinib-induced pulmonary arterial hypertension. Br J Clin Pharmacol. 2018;84(5):835–845.
   PubMed Web of Science ®Google Scholar
• Paydas S. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect? Crit Rev Oncol Hematol. 2014;89(2):242–247.
   PubMed Web of Science ®Google Scholar
• Schiffer CA, Cortes JE, Hochhaus A, et al., Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: effects on response and toxicity. Cancer. 2016;122(9):1398–1407.
   PubMed Web of Science ®Google Scholar
• Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116(2):377–386.
   PubMed Web of Science ®Google Scholar
• Iurlo A, Galimberti S, Abruzzese E, et al. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Ann Hematol. 2018;97(1):95–100.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Eyice D, Kurt EA, et al., Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leuk Res. 2014;38(7):781–787.
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658–6661.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jimenez CA, Mauro MJ, et al. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk. 2017;17(2):78–82.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, O’brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908–3914.
   PubMed Web of Science ®Google Scholar
• Phan C, Jutant EM, Tu L, et al. Dasatinib increases endothelial permeability leading to pleural effusion. Eur Respir J. 2018;51(1):1701096.
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Fava C, et al. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol. 2013;31(2):103–109.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Laneuville P, Rousselot P, et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 2019;104(1):93–101.
   PubMed Web of Science ®Google Scholar
• Ercaliskan A, Eskazan AE. Bosutinib – an effective and safe treatment option in the management of chronic myeloid leukemia. Future Oncol. 2020;4425-4428.
   Google Scholar
• Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinibresistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66(23):11314–11322.
   PubMed Web of Science ®Google Scholar
• Moguillansky NI, Fakih HAM, Wingard JR Bosutinib induced pleural effusions: case report and review of tyrosine kinase inhibitors induced pulmonary toxicity. Respir Med Case Rep. 2017;21:154–157.
   Google Scholar
• Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486‐3492.
   Web of Science ®Google Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al., Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–237.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib blood. Blood. 2011;118(17):4567–4576.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Khoury HJ, Kantarjian HM, et al., Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016;91(12):1206–1214.
   PubMed Web of Science ®Google Scholar
• García-Gutiérrez V, Milojkovic D, Hernandez-Boluda JC, et al. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. Ann Hematol. 2019;98(2):321–330.
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Abruzzese E, Capodanno I, et al. Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under Dasatinib therapy. Ann Hematol. 2019;98(11):2609–2611.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Gambacorti-Passerini C, Abboud C, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34(8):2125–2137.
   Web of Science ®Google Scholar